Biochemical and Pharmacological Mechanisms of GLP-1 and Dual Agonists: Implications for Glycemic Control and Cardiovascular Risk Reduction — A Review
- 12 January 2026
- journal article
- review article
- Published by KMF Publishers in Journal of Biochemistry Pharmacology and Public Health
- Vol. 4 (1)
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists and dual incretin agonists, particularly glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor co-agonists, represent a major therapeutic advancement in the management of type 2 diabetes mellitus (T2DM) and obesity. Beyond glycemic control, these agents demonstrate clinically significant benefits in weight reduction, blood pressure modulation, lipid profile improvement, and cardiovascular risk mitigation. This review synthesises biochemical, molecular, and pharmacological mechanisms underlying the clinical effectiveness of GLP-1 receptor agonists and dual agonists such as semaglutide and tirzepatide. Guided by a translational biomedical framework integrating receptor signalling theory and cardiometabolic risk models, this qualitative systematic narrative review evaluates peer-reviewed literature on metabolic pathways, neuroendocrine signalling, inflammatory modulation, and endothelial function. Findings suggest that dual agonists provide additive and potentially synergistic metabolic benefits through complementary receptor activation, enhancing insulin sensitivity, appetite regulation, and vascular protection. The review highlights implications for cardiovascular disease prevention, therapeutic guidelines, and future drug development. Limitations include heterogeneity in clinical trial populations and evolving long-term safety data. Future research should prioritise mechanistic human studies, real-world cardiovascular outcomes, and equity in drug access. Keywords: GLP-1 receptor agonists, dual incretin agonists, tirzepatide, semaglutide, cardiovascular risk, type 2 diabetes, obesity, pharmacologyKeywords
This publication has 15 references indexed in Scilit:
- Tirzepatide Once Weekly for the Treatment of ObesityNew England Journal of Medicine, 2022
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesNew England Journal of Medicine, 2021
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine, 2021
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialThe Lancet, 2019
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of conceptMolecular Metabolism, 2018
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1Cell Metabolism, 2018
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trialThe Lancet Diabetes & Endocrinology, 2018
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone ActionCell Metabolism, 2013
- Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.Journal of Biological Chemistry, 1992